HLS Therapeutics: Up after Health Canada approves Schizophrenia treatment

HLS Therapeutics

17/11/2020 17:28

** Shares of Canadian pharma company  HLS.TO  up 4.4% at
C$16.07
    ** Co says Health Canada has approved use of Perseris, a 90
mg and 120 mg subcutaneous injection, for the treatment of
schizophrenia in adults  urn:newsml:reuters.com:*:nCNWcvR8Da
    ** HLS has in-licensed exclusive rights to Perseris for the
Canadian market from Indivior PLC 
    ** Stock down 37% YTD 

 (Reporting by Shradha Singh in Bengaluru)
 ((Shradha.Singh@thomsonreuters.com; within U.S. +1 646 223 8780
Ext: 2804, outside U.S. +91 80 6182 2630;))